Key Topics of Discussion:
- Current Research in Melanoma Treatment: Explore the latest studies and emerging therapies that are transforming the landscape of melanoma care.
- Neoadjuvant Immunotherapy Studies: A closer look at how immunotherapy is being used before surgery to enhance patient outcomes.
- Second-Line Therapies for Metastatic Melanoma: Understanding new treatment options for patients whose melanoma has spread and does not respond to initial treatments.
- Cancer Vaccines: Examining the role of vaccines in melanoma treatment and their potential to prevent recurrence.
This insightful conversation will provide patients, caregivers, and advocates with valuable knowledge directly from two leaders in melanoma oncology.
About Our Guests:
Michael A. Davies, M.D., Ph.D.
Professor and Chairman of the Department of Melanoma Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center
Dr. Davies is a recognized leader in the management of advanced melanoma, specializing in immunotherapy, targeted therapies, and chemotherapy. He has designed and led numerous clinical trials aimed at improving outcomes for patients with advanced melanoma. Dr. Davies’ laboratory research focuses on understanding oncogenic mutations, overcoming resistance to treatments, and exploring new therapeutic strategies for melanoma, including those targeting central nervous system metastases.
Hussein A. Tawbi, M.D., Ph.D.
Professor and Deputy Chair of the Department of Melanoma Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center
Dr. Tawbi is an expert in personalized cancer therapies for melanoma, with a focus on developing tailored treatments for patients based on genetic and molecular characteristics. As a director of personalized cancer therapy at MD Anderson, Dr. Tawbi’s research aims to improve treatment strategies for metastatic melanoma and investigate new ways to personalize and optimize therapy for each patient.